Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
Marc Nash, SVP Operations and R&D and director of Outset Medical (OM), reported a non-discretionary sell-to-cover transaction on 08/15/2025. He sold 243 shares of Outset common stock at $12.88 per share to satisfy tax withholding related to the vesting of an aggregate 673 restricted stock units granted on March 15, 2023, July 24, 2023, and January 12, 2024. After the transaction, the reporting person beneficially owned 42,898 shares directly. The Form 4 was signed by John L. Brottem on behalf of Marc Nash on 08/18/2025.
This filing is a routine insider tax-withholding sale and the filer states it was not a discretionary trade.
John L. Brottem, General Counsel and director of Outset Medical, reported a routine sell-to-cover transaction on 08/15/2025. He sold 383 shares of Outset Medical common stock at $12.88 per share to satisfy tax withholding obligations arising from the vesting of 748 RSU shares awarded on January 6, 2023 and January 12, 2024. After the transaction, Brottem beneficially owned 46,883 shares directly. The filing specifies the sale was to cover taxes and was not a discretionary trade by the reporting person.
Outset Medical, Inc. insider filing reports a proposed Rule 144 sale of 904 shares of common stock via Morgan Stanley Smith Barney, with an aggregate market value of $11,643.52 and an approximate sale date of 08/15/2025. The shares were acquired the same day, 08/15/2025, as the settlement of vested restricted stock units issued as equity compensation for services rendered. The filer also disclosed a prior sale on 05/15/2025 of 935 shares for gross proceeds of $16,646.12. Outstanding common shares are listed as 17,766,193, indicating the transactions are a small fraction of total shares outstanding. The filing includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Outset Medical, Inc. (OM) reported a proposed sale under Rule 144 of 383 shares of Common Stock through Morgan Stanley Smith Barney, with an aggregate market value of $4,933.04, targeted for sale on 08/15/2025 on NASDAQ. The filing shows the securities were acquired as settlement of vested restricted stock units on 08/15/2025 (748 shares) as equity compensation. The filer also reports a prior sale of 396 shares on 05/15/2025 that generated $7,057.86. The notice includes the customary representation that the seller is not aware of undisclosed material adverse information.
Form 144 filing for Outset Medical, Inc. (OM) documents a proposed sale of 243 shares of Common Stock through Morgan Stanley Smith Barney with an aggregate market value of $3,129.84, to be sold on 08/15/2025 on NASDAQ. The shares were acquired on 08/15/2025 as settlement of vested restricted stock units and were paid as equity compensation for services. The filer also disclosed a prior sale of 252 shares on 05/15/2025 generating gross proceeds of $4,490.50. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.